JY
SNDX icon

Jeff Yass’s Syndax Pharmaceuticals SNDX Stock Holding History

Jeff Yass’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.93M Buy
454,101
+257,480
+131% +$5.35M ﹤0.01% 3425
2026
Q1 		$4.59M Buy
196,621
+178,468
+983% +$3.88M ﹤0.01% 4382
2025
Q4 		$381K Sell
18,153
-16,597
-48% -$290K ﹤0.01% 9410
2025
Q3 		$535K Sell
34,750
-336,713
-91% -$4.41M ﹤0.01% 8784
2025
Q2 		$3.48M Buy
371,463
+41,557
+13% +$457K ﹤0.01% 4673
2025
Q1 		$4.05M Buy
329,906
+202,349
+159% +$2.85M ﹤0.01% 4052
2024
Q4 		$1.69M Sell
127,557
-41,149
-24% -$704K ﹤0.01% 5696
2024
Q3 		$3.25M Buy
168,706
+66,679
+65% +$1.38M ﹤0.01% 4394
2024
Q2 		$2.09M Sell
102,027
-634,121
-86% -$13.3M ﹤0.01% 5015
2024
Q1 		$17.5M Buy
736,148
+711,751
+2,917% +$15.9M ﹤0.01% 1924
2023
Q4 		$527K Sell
24,397
-92,493
-79% -$1.42M ﹤0.01% 8541
2023
Q3 		$1.7M Buy
116,890
+98,220
+526% +$1.86M ﹤0.01% 5470
2023
Q2 		$391K Sell
18,670
-90,655
-83% -$1.89M ﹤0.01% 8887
2023
Q1 		$2.31M Buy
109,325
+88,637
+428% +$2.2M ﹤0.01% 4839
2022
Q4 		$527K Sell
20,688
-35,401
-63% -$826K ﹤0.01% 7723
2022
Q3 		$1.35M Buy
+56,089
New +$1.26M ﹤0.01% 5858
2022
Q2 		– Sell
-115,094
Closed -$1.92M – 13865
2022
Q1 		$2M Buy
115,094
+23,566
+26% +$397K ﹤0.01% 5477
2021
Q4 		$2M Sell
91,528
-242,278
-73% -$4.48M ﹤0.01% 5492
2021
Q3 		$6.38M Buy
333,806
+225,948
+209% +$3.77M ﹤0.01% 3539
2021
Q2 		$1.85M Sell
107,858
-46,976
-30% -$860K ﹤0.01% 6091
2021
Q1 		$3.46M Buy
154,834
+145,684
+1,592% +$3.29M ﹤0.01% 4654
2020
Q4 		$203K Buy
+9,150
New +$190K ﹤0.01% 10015
2020
Q1 		– Sell
-16,129
Closed -$151K – 10830
2019
Q4 		$142K Sell
16,129
-18,932
-54% -$139K ﹤0.01% 8979
2019
Q3 		$262K Buy
+35,061
New +$319K ﹤0.01% 8595
2019
Q1 		– Sell
-64,882
Closed -$370K – 9769
2018
Q4 		$289K Sell
64,882
-33,508
-34% -$184K ﹤0.01% 7076
2018
Q3 		$795K Buy
+98,390
New +$701K ﹤0.01% 5677

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Jeff Yass's SNDX Position: Q2 2026 in Review

Jeff Yass increased its Syndax Pharmaceuticals (SNDX) stake by 131% in Q2 2026, buying an estimated $5.35M and bringing the position to 454,101 shares worth $9.93M. The position accounts for ﹤0.01% of the portfolio, ranked #3425.

Jeff Yass first reported a position in SNDX in Q3 2018 and has held it in 26 quarters since. The position peaked at $17.5M in Q1 2024. 240 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Jeff Yass held 454,101 shares of Syndax Pharmaceuticals worth $9.93M as of Q2 2026.
  • Jeff Yass bought 257,480 Syndax Pharmaceuticals shares in Q2 2026, an estimated $5.35M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3425 holding.
  • Jeff Yass first reported a position in Syndax Pharmaceuticals in Q3 2018 and has held it in 26 quarters since.
  • Jeff Yass's Syndax Pharmaceuticals position peaked at $17.5M in Q1 2024.
  • 240 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.